Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN FibroGen, Inc. daily Stock Chart
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own4.50% Shs Outstand91.60M Perf Week-9.96%
Market Cap3.58B Forward P/E- EPS next Y-1.13 Insider Trans-12.27% Shs Float75.71M Perf Month-9.80%
Income-74.30M PEG- EPS next Q-0.13 Inst Own66.50% Short Float3.77% Perf Quarter-33.38%
Sales147.40M P/S24.26 EPS this Y1.00% Inst Trans-0.17% Short Ratio4.83 Perf Half Y-31.93%
Book/sh5.58 P/B7.00 EPS next Y- ROA-14.80% Target Price71.00 Perf Year-13.72%
Cash/sh7.13 P/C5.48 EPS next 5Y- ROE-26.00% 52W Range37.27 - 68.55 Perf YTD-17.64%
Dividend- P/FCF- EPS past 5Y-10.70% ROI-10.50% 52W High-40.98% Beta2.14
Dividend %- Quick Ratio6.80 Sales past 5Y13.80% Gross Margin- 52W Low8.56% ATR2.43
Employees423 Current Ratio6.80 Sales Q/Q-28.60% Oper. Margin-88.50% RSI (14)45.57 Volatility7.03% 5.63%
OptionableYes Debt/Eq0.24 EPS Q/Q-56.20% Profit Margin-87.80% Rel Volume0.50 Prev Close39.04
ShortableYes LT Debt/Eq0.24 EarningsNov 08 AMC Payout- Avg Volume590.22K Price40.46
Recom1.80 SMA20-0.70% SMA50-12.51% SMA200-24.55% Volume99,775 Change3.64%
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Citigroup Buy
Sep-23-15Initiated Lake Street Hold $25
Jul-29-15Initiated Citigroup Buy $37
Jul-20-15Upgrade Goldman Neutral → Buy
Dec-09-14Initiated Stifel Buy $39
Dec-09-14Initiated RBC Capital Mkts Outperform $38
Dec-06-18 04:00AM  FibroGen Appoints Maykin Ho, Ph.D., to Board of Directors GlobeNewswire
Nov-27-18 08:45AM  New Research Coverage Highlights Phibro Animal Health, RadNet, Amphastar Pharmaceuticals, FibroGen, Sientra, and Flexion Therapeutics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-16-18 11:47AM  Edited Transcript of FGEN earnings conference call or presentation 8-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 06:55AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and FibroGen ACCESSWIRE
Nov-08-18 06:40PM  FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:35PM  FibroGen: 3Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 01:55PM  What Kind Of Shareholder Appears On The FibroGen Incs (NASDAQ:FGEN) Shareholder Register? Simply Wall St. -5.91%
Nov-02-18 05:02PM  FibroGen to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 GlobeNewswire
Oct-30-18 04:00AM  ASN Kidney Week 2018: Data Presented from Two Japanese Phase 3 Studies on Roxadustat in the Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Oct-25-18 07:49PM  FibroGen Presents Results from Two Phase 3 Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire
Oct-18-18 08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and FibroGen ACCESSWIRE
Oct-16-18 04:27PM  FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting GlobeNewswire +7.75%
08:30AM  Research Report Identifies The Habit Restaurants, Datawatch, SMART SAND INC, Independence Contract Drilling, Pareteum, and FibroGen with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-01-18 08:00AM  Astellas Submits New Drug Application in Japan of Roxadustat for The Treatment of Anemia Associated with Chronic Kidney Disease in Patients on Dialysis GlobeNewswire
Sep-28-18 03:09PM  All You Need To Know About FibroGen Incs (NASDAQ:FGEN) Financial Health Simply Wall St.
Sep-25-18 08:00AM  Today's Research Reports on Trending Tickers: Ultragenyx Pharmaceutical and FibroGen ACCESSWIRE
Sep-24-18 11:10AM  Health Care Digest: Genentech's neuro legacy, uBiome's haul, plus saving moms American City Business Journals
Sep-19-18 03:02AM  Focus: AstraZeneca plots China robot offensive to counter price cuts Reuters
02:03AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
01:08AM  AstraZeneca plots China robot offensive to counter price cuts Reuters
Sep-12-18 09:30AM  FibroGen Receives Fast Track Designation From the U.S. FDA for Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-05-18 05:19AM  Boost for "made in China" medicine as Chi-Med wins key approval Reuters
Aug-15-18 07:55AM  New Research: Key Drivers of Growth for comScore, Fonar, FibroGen, Resolute Energy, National Commerce, and THL Credit Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-07-18 07:20PM  FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
06:13PM  FibroGen: 2Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 05:21PM  FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018 GlobeNewswire
Jul-10-18 07:45AM  Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 07:00AM  Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
Jun-07-18 07:00AM  FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease GlobeNewswire
Jun-04-18 02:05PM  FibroGen to Present at Two Upcoming Investor Conferences GlobeNewswire
Jun-03-18 09:30PM  FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting GlobeNewswire
Jun-01-18 09:30AM  FibroGen Inc (NASDAQ:FGEN) Investors Are Paying Above The Intrinsic Value Simply Wall St.
May-21-18 04:00PM  FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018 GlobeNewswire
May-15-18 05:29PM  FibroGen Upgraded By Mizuho On Continued R&D Progress Benzinga
May-10-18 06:06PM  Edited Transcript of FGEN earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents -5.61%
May-09-18 05:31PM  FibroGen: 1Q Earnings Snapshot Associated Press
04:02PM  FibroGen Reports First Quarter 2018 Financial Results GlobeNewswire
May-02-18 07:00AM  FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018 GlobeNewswire
Apr-27-18 07:45AM  Consolidated Research: 2018 Summary Expectations for MGM Growth Properties, Reinsurance Group of America, Cincinnati Bell, GAIN Capital, FibroGen, and First Hawaiian Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-05-18 07:40AM  Wired News FDA Granted Fast Track Designation to FibroGens Pamrevlumab for Locally Advanced Unresectable Pancreatic Cancer ACCESSWIRE
Mar-02-18 06:11PM  Edited Transcript of FGEN earnings conference call or presentation 27-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Mar-01-18 01:45PM  UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
07:55AM  Report: Developing Opportunities within Main Street Capital, United States Cellular, FibroGen, Cardiovascular, CDW, and ANSYS Future Expectations, Projections Moving into 2018 GlobeNewswire
07:00AM  Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer GlobeNewswire
Feb-28-18 05:04AM  FibroGen reports 4Q loss Associated Press -5.73%
Feb-27-18 04:11PM  FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
01:30PM  FibroGen, Inc. to Host Earnings Call ACCESSWIRE
12:53PM  FibroGen Q4 Earnings Outlook Benzinga
07:27AM  FibroGen Incs (NASDAQ:FGEN) Earnings Dropped -74.69%, Did Its Industry Show Weakness Too? Simply Wall St.
Feb-21-18 07:00AM  FibroGen to Report Fourth Quarter and Full Year 2017 Financial Results on Tuesday, February 27, 2018 GlobeNewswire
Feb-17-18 01:18PM  Why FibroGen Inc (NASDAQ:FGEN) Is A Financially Healthy Company Simply Wall St.
Jan-04-18 07:40AM  Report: Exploring Fundamental Drivers Behind K2M Group, Altra Industrial Motion, FibroGen, Cardiovascular, Bluerock Residential Growth REIT, and National Presto Industries New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -5.27%
Jan-02-18 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit +6.96%
Jan-01-18 07:44AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : January 1, 2018 Capital Cube
Dec-27-17 11:15AM  ETFs with exposure to FibroGen, Inc. : December 27, 2017 Capital Cube
Dec-15-17 01:21PM  ETFs with exposure to FibroGen, Inc. : December 15, 2017 Capital Cube
Dec-14-17 08:15PM  Edited Transcript of FGEN earnings conference call or presentation 8-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Nov-27-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Nov-20-17 12:27PM  ETFs with exposure to FibroGen, Inc. : November 20, 2017 Capital Cube
Nov-15-17 08:07AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
07:10AM  Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU ACCESSWIRE
Nov-14-17 07:30AM  Featured Company News - FDA Approved Teligent's Betamethasone Dipropionate Ointment USP (Augmented), 0.05% ACCESSWIRE
Nov-13-17 09:34AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Capital Cube
Nov-10-17 08:14AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
07:58AM  FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017 Capital Cube
Nov-08-17 06:07PM  ETFs with exposure to FibroGen, Inc. : November 8, 2017 Capital Cube
05:31PM  FibroGen reports 3Q loss Associated Press
04:02PM  FibroGen Reports Third Quarter 2017 Financial Results GlobeNewswire
02:10PM  FibroGen, Inc. to Host Earnings Call ACCESSWIRE
07:29AM  Is It Too Late To Buy FibroGen Inc (FGEN)? Simply Wall St.
Oct-30-17 08:00PM  FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017 GlobeNewswire
Oct-24-17 09:38AM  ETFs with exposure to FibroGen, Inc. : October 24, 2017 Capital Cube
Oct-18-17 09:29AM  Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers TheStreet.com
07:00AM  FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD) GlobeNewswire
Oct-17-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Oct-13-17 10:47AM  ETFs with exposure to FibroGen, Inc. : October 13, 2017 Capital Cube
Oct-10-17 07:04PM  Cramer's lightning round: Let Nike walk these losses off CNBC Videos
Oct-02-17 11:14AM  3 Under-the-Radar Small Cap Gems Investopedia
10:50AM  ETFs with exposure to FibroGen, Inc. : October 2, 2017 Capital Cube
Sep-30-17 07:17AM  FibroGen Inc (FGEN): How Does It Impact Your Portfolio? Simply Wall St.
Sep-29-17 09:03AM  FibroGen, Inc. :FGEN-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017 Capital Cube
Sep-28-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Sep-19-17 04:35PM  FibroGen Appoints Gerald Lema to Board of Directors GlobeNewswire
Sep-13-17 04:33PM  Why This Cancer Biotech Leads Pack After Hitting Record High Investor's Business Daily
07:00AM  Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017 GlobeNewswire
Sep-06-17 07:14PM  Is There Now An Opportunity In FibroGen Inc (FGEN)? Simply Wall St.
Sep-05-17 04:05PM  FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017 GlobeNewswire
Aug-17-17 09:26AM  Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment TheStreet.com
Aug-15-17 11:32PM  FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock GlobeNewswire -6.24%
Aug-14-17 04:26PM  FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock GlobeNewswire +5.76%
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about FibroGen Inc. Markit
Aug-11-17 11:45PM  Edited Transcript of FGEN earnings conference call or presentation 7-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-10-17 08:03AM  IHS Markit Score Update: Drop in demand for ETFs holding FibroGen Inc is a negative sign for its shares Markit -5.84%
Aug-09-17 08:46AM  Biotech Stock Roundup: Q2 Earnings from Regeneron, Kite & More, FibroGen Up on IPF Data Zacks -11.82%
08:43AM  Strength Seen in FibroGen (FGEN): Stock Soars 48.2% Zacks
Aug-08-17 04:20PM  Why Ralph Lauren, LendingClub, and FibroGen Jumped Today Motley Fool +48.20%
03:06PM  Why Did FibroGen (FGEN) Stock Hit All-Time High Today? Zacks
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Neff Thomas BChief Executive OfficerDec 06Option Exercise3.6011,00239,6072,650,949Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerDec 06Sale40.9328,1641,152,6662,622,785Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerDec 06Sale40.911,83675,11187,450Dec 06 08:45 PM
Neff Thomas BChief Executive OfficerNov 21Option Exercise3.6010,31937,1482,667,507Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 21Sale39.4718,900745,9832,648,607Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 21Sale39.4791836,23389,286Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Option Exercise3.6010,31937,1482,676,088Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Sale39.2618,900742,0412,657,188Nov 21 06:23 PM
Neff Thomas BChief Executive OfficerNov 20Sale39.2591836,03190,204Nov 21 06:23 PM
Kurkijarvi KaleviDirectorNov 15Option Exercise2.904,00011,60027,700Nov 16 06:24 PM
Rosenkranz Roberto PedroDirectorNov 15Option Exercise9.781,0009,77533,700Nov 16 06:28 PM
Kurkijarvi KaleviDirectorNov 15Sale39.774,000159,09423,700Nov 16 06:24 PM
Rosenkranz Roberto PedroDirectorNov 15Sale39.241,00039,24032,700Nov 16 06:28 PM
Neff Thomas BChief Executive OfficerNov 02Option Exercise3.6010,31937,1482,684,669Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 02Sale44.6018,900842,8662,665,769Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 02Sale44.6191840,95291,122Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 01Option Exercise3.6010,31937,1482,693,250Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 01Sale44.0418,900832,3382,674,350Nov 02 06:40 PM
Neff Thomas BChief Executive OfficerNov 01Sale44.0891840,46592,040Nov 02 06:40 PM
Schoeneck James ADirectorOct 30Option Exercise13.8924,000333,30027,700Nov 01 01:48 PM
Neff Thomas BChief Executive OfficerOct 19Option Exercise3.6010,31937,1482,701,831Oct 19 08:37 PM
Neff Thomas BChief Executive OfficerOct 19Sale53.9218,9001,019,1102,682,931Oct 19 08:37 PM
Neff Thomas BChief Executive OfficerOct 19Sale53.6991849,28592,958Oct 19 08:37 PM
Neff Thomas BChief Executive OfficerOct 18Option Exercise3.6010,31937,1482,710,412Oct 19 08:37 PM
Kurkijarvi KaleviDirectorOct 18Option Exercise2.904,00011,60027,700Oct 19 08:40 PM
Rosenkranz Roberto PedroDirectorOct 18Option Exercise9.781,0009,77533,700Oct 19 08:41 PM
Neff Thomas BChief Executive OfficerOct 18Sale54.5218,9001,030,4432,691,512Oct 19 08:37 PM
Neff Thomas BChief Executive OfficerOct 18Sale54.5691850,08893,876Oct 19 08:37 PM
Kurkijarvi KaleviDirectorOct 18Sale55.424,000221,67023,700Oct 19 08:40 PM
Rosenkranz Roberto PedroDirectorOct 18Sale55.391,00055,38732,700Oct 19 08:41 PM
Neff Thomas BChief Executive OfficerOct 03Option Exercise3.6010,31937,1482,718,993Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerOct 03Sale59.4518,9001,123,6902,700,093Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerOct 03Sale59.4991854,60894,794Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerOct 02Option Exercise3.6010,32037,1522,727,574Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerOct 02Sale58.8318,9001,111,9152,708,674Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerOct 02Sale58.9291854,08595,712Oct 04 06:00 PM
Neff Thomas BChief Executive OfficerSep 20Option Exercise3.6010,32037,1522,736,154Sep 21 06:15 PM
Rosenkranz Roberto PedroDirectorSep 20Option Exercise9.781,0009,77533,700Sep 21 06:16 PM
Neff Thomas BChief Executive OfficerSep 20Sale58.7418,9001,110,1652,717,254Sep 21 06:15 PM
Neff Thomas BChief Executive OfficerSep 20Sale58.8791854,04196,630Sep 21 06:15 PM
Rosenkranz Roberto PedroDirectorSep 20Sale56.951,00056,95032,700Sep 21 06:16 PM
Neff Thomas BChief Executive OfficerSep 19Option Exercise3.6010,32037,1522,744,734Sep 21 06:15 PM
Neff Thomas BChief Executive OfficerSep 19Sale56.8718,9001,074,7722,725,834Sep 21 06:15 PM
Neff Thomas BChief Executive OfficerSep 19Sale56.8891852,22097,548Sep 21 06:15 PM
Kurkijarvi KaleviDirectorSep 17Option Exercise2.904,00011,60027,700Sep 18 06:16 PM
Kurkijarvi KaleviDirectorSep 17Sale58.864,000235,45623,700Sep 18 06:16 PM
Cotroneo PatSVP, Finance and CFOSep 13Sale59.502,318137,921228,604Sep 14 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 12Option Exercise2.9010,50030,450230,922Sep 14 05:19 PM
Routti JormaDirectorSep 10Option Exercise18.346,000110,040137,540Sep 12 04:54 PM
Routti JormaDirectorSep 10Sale57.316,000343,837131,540Sep 12 04:54 PM
Cotroneo PatSVP, Finance and CFOSep 10Sale57.351,01157,981220,422Sep 12 04:57 PM
Neff Thomas BChief Executive OfficerSep 07Option Exercise3.6010,32037,1522,753,314Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 07Sale56.7518,9001,072,6002,734,414Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 07Sale56.7491852,08498,466Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Option Exercise3.6010,32037,1522,761,894Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Sale58.2918,9001,101,5992,742,994Sep 07 06:28 PM
Neff Thomas BChief Executive OfficerSep 06Sale57.9791853,21699,384Sep 07 06:28 PM
Yu K PeonyChief Medical OfficerAug 31Option Exercise12.296,80083,585154,269Sep 05 06:37 PM
Tamura ToshinariDirectorAug 22Option Exercise19.0512,000228,60063,700Aug 24 07:25 PM
Tamura ToshinariDirectorAug 22Sale60.6512,000727,80051,700Aug 24 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Option Exercise3.6010,32037,1522,779,133Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Sale60.5518,9001,144,3202,760,233Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 21Sale60.5991855,622100,302Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Option Exercise3.6010,32037,1522,787,713Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Sale59.9418,9001,132,9092,768,813Aug 22 07:25 PM
Neff Thomas BChief Executive OfficerAug 20Sale59.8291854,915101,220Aug 22 07:25 PM
Kurkijarvi KaleviDirectorAug 16Option Exercise2.904,00011,60027,700Aug 17 05:25 PM
Rosenkranz Roberto PedroDirectorAug 16Option Exercise9.781,0009,77533,700Aug 17 05:28 PM
Kurkijarvi KaleviDirectorAug 16Sale60.284,000241,12823,700Aug 17 05:25 PM
Rosenkranz Roberto PedroDirectorAug 16Sale60.281,00060,27932,700Aug 17 05:28 PM
Routti JormaDirectorAug 09Option Exercise18.006,000108,000137,540Aug 10 04:48 PM
Routti JormaDirectorAug 09Sale59.936,000359,579131,540Aug 10 04:48 PM
Neff Thomas BChief Executive OfficerAug 02Option Exercise3.6010,32037,1522,796,293Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 02Sale62.9018,9001,188,7232,777,393Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 02Sale62.8891857,724102,138Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Option Exercise3.6010,32037,1522,804,873Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Sale63.1118,9001,192,8472,785,973Aug 03 04:58 PM
Neff Thomas BChief Executive OfficerAug 01Sale63.0891857,907103,056Aug 03 04:58 PM
Kurkijarvi KaleviDirectorJul 19Option Exercise2.904,00011,60027,700Jul 20 06:07 PM
Neff Thomas BChief Executive OfficerJul 19Option Exercise3.6010,32037,1522,813,453Jul 20 06:08 PM
Rosenkranz Roberto PedroDirectorJul 19Option Exercise9.781,0009,77533,700Jul 20 06:10 PM
Kurkijarvi KaleviDirectorJul 19Sale64.354,000257,40023,700Jul 20 06:07 PM
Neff Thomas BChief Executive OfficerJul 19Sale64.3418,9001,216,0722,794,553Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 19Sale64.2791859,000103,974Jul 20 06:08 PM
Rosenkranz Roberto PedroDirectorJul 19Sale64.901,00064,90032,700Jul 20 06:10 PM
Neff Thomas BChief Executive OfficerJul 18Option Exercise3.6010,32037,1522,822,033Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 18Sale65.4818,9001,237,5992,803,133Jul 20 06:08 PM
Neff Thomas BChief Executive OfficerJul 18Sale65.4891860,111104,892Jul 20 06:08 PM
Routti JormaDirectorJul 09Option Exercise18.006,000108,000137,540Jul 11 06:59 PM
Routti JormaDirectorJul 09Sale67.716,000406,260131,540Jul 11 06:59 PM
Neff Thomas BChief Executive OfficerJul 06Option Exercise3.6010,32037,1522,830,613Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 06Sale65.8118,9001,243,8532,811,713Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 06Sale66.0291860,608105,810Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Option Exercise3.6010,32037,1522,839,193Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Sale64.1618,9001,212,5432,820,293Jul 06 08:02 PM
Neff Thomas BChief Executive OfficerJul 05Sale64.0191858,762106,728Jul 06 08:02 PM
Schoeneck James ADirectorJul 03Option Exercise2.907,63922,15311,339Jul 06 08:04 PM
Yu K PeonyChief Medical OfficerJul 03Option Exercise14.5815,645228,026163,114Jul 06 08:06 PM
Schoeneck James ADirectorJul 03Sale65.007,639496,5353,700Jul 06 08:04 PM
Yu K PeonyChief Medical OfficerJul 03Sale65.0015,6451,016,925147,469Jul 06 08:06 PM